Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

128.89 -2.75 (-2.09%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Neurocrine Biosciences, Inc. - Common Stock

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)

April 06, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 30, 2025

From Fate Therapeutics, Inc.

Via GlobeNewswire

New Study Reveals How Classical Music Could Revolutionize Depression Care

August 12, 2024

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...

Via PressReach

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

April 16, 2024

From Sentia Medical Sciences, Inc.

Via GlobeNewswire

The 5 Stocks Most Sold By Insiders This Year

April 16, 2024

Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices.

Via MarketBeat

Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

December 29, 2023

Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.

Via MarketBeat

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

February 14, 2023

From Sentia Medical Sciences, Inc.

Via GlobeNewswire

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

January 25, 2023

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

Via MarketBeat

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

November 11, 2022

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

Via MarketBeat

Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors

September 29, 2022

Via AB Newswire

Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027

May 05, 2021

Via FinancialNewsMedia

Biotechs Aligning to Address Challenges for Developing Therapeutics for Billion Dollar Neurological Disorders Industry

April 22, 2021

Via FinancialNewsMedia

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.